Hainan Huluwa Pharmaceutical Group Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Hainan Huluwa Pharmaceutical Group Co., Ltd. takes "Healthy Chinese Children" as its corporate mission, safeguarding the healthy growth of Chinese children, and is committed to becoming the "number one brand of pediatric medicine in China". Huluwa Pharmaceutical Group is a conglomerate headquartered in Haikou. It was restructured in 2008 and listed on the main board of the Shanghai Stock Exchange in July 2020 (stock abbreviation: Huluwa, stock code: 605199). It is the first listed enterprise in Hainan since the announcement of the overall plan for the construction of Hainan Free Trade Port. After more than ten years of hard work, the group has worked diligently in the field of pediatric medicine and has now developed into one of the leading enterprises in the professional pediatric pharmaceutical field. It has been selected as the Vice Chairman Unit of the Pediatric Branch of the Chinese Traditional Chinese Medicine Association for two consecutive terms. Huluwa Pharmaceutical Group focuses on research and development innovation, lean production, and marketing transformation. It has established six intelligent manufacturing bases, including Haikou Pharmaceutical Valley Production Base, Haikou Bonded Production Base, Guangxi Nanning Production Base, and Guangxi Laibin Traditional Chinese Medicine Extraction Base. The Haikou Mei'an Children's Medicine Intelligent Manufacturing Base project is being accelerated and has 47 advanced production lines; There are a total of 36 children's medicine varieties in production and sales (all with clear usage and dosage for children), with main products including Children's Lung Heat and Cough Granules, Yanyanning Granules, and about 110 products under research; The sales network covers over 2300 counties and cities in all provinces within the country. Huluwa Pharmaceutical Group is one of the first high-tech leading enterprises, high growth headquarters enterprises, and specialized, refined, and innovative enterprises in Hainan Province. It was ranked among the top 100 enterprises and top 40 manufacturing enterprises in Hainan Province in 2022, ranking 45th among the top 100 traditional Chinese medicine enterprises in the Chinese pharmaceutical industry, 24th among China's over-the-counter drug production enterprises, and top 10 in China's traditional Chinese medicine research and development strength, And for three consecutive years in 2017, 2018, and 2019, as a representative brand of Chinese pediatric medicine, it was selected as a "CCTV Big Country Brand", leading the development of Chinese pediatric medicine brands. In addition, the group has successively established academician workstations, postdoctoral research workstations, and engineering technology research centers, and has won the Outstanding Contribution Award of "Tailored Children's Drugs" from the World Health Organization Asia Pacific Cooperation Center. At the same time, after the group went public, it integrated various management work into ESG governance and actively assumed social responsibility. It launched public welfare projects such as a public lecture on safe drug use for children and a "Spring Bud Class" for donating funds for girls to attend. For six consecutive years, it donated and comforted the Haikou Social Welfare Institute. After the outbreak of the COVID-19, the Group actively organized the resumption of work and production, donated urgently needed materials to fight the epidemic, helped the local fight against the epidemic, and won the Special Contribution Award of the Red Cross Society of China for COVID-19 prevention and control. Huluwa Pharmaceutical Group has embarked on a new journey of "secondary entrepreneurship", adhering to the Party building leading high-quality development of enterprises, adhering to the corporate purpose of "patriotism, struggle, standardization, and innovation", continuously deepening transformation with new development concepts, continuously improving product quality and craftsmanship level with craftsmanship spirit, winning market recognition with professional services, creating a national brand in the pediatric industry, and striving to become a guardian of China's children's health field, Make New and Greater Contributions to the Healthy China Strategy!. |
| Headquarter | Haikou |
| Establish Date | 6/22/2005 |
| Listed Code | 605199.SH |
| Listed Date | 7/10/2020 |
| Chairman | Liu Jingping. |
| CEO | Liu Jingping. |
| Website | www.huluwayaoye.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
